Name: 글로벌 시장 동향
SKU: PH7728
Availability: InStock

보고서 요약(국문)

개요
전 세계 DDR 결함 종양 시장은 2022년 XX백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 XX%의 성장률을 보이며 2030년에는 XX백만 달러에 이를 것으로 예상됩니다.
DDR 결함은 종양 세포의 고유한 특성으로, 암 발생뿐만 아니라 암의 진행 및 전이에도 상당한 영향을 미칩니다. 진행된 DDR 유전자 변형과 유전체 불안정성은 전이성 성장의 특징입니다. 세포의 DDR(DNA 손상 반응) 결핍은 DNA 돌연변이를 증가시켜 종양 형성을 촉진하며, 이는 합성 치사 기반 치료법으로 표적화될 수 있는 암 특이적 감수성을 유발하기도 합니다.
시장 동향: 성장 동인 및 제약 요인
임상 연구 발전 증가
예측 기간 동안 DDR 결함 종양에 대한 임상 연구 발전이 증가함에 따라 전 세계 시장 성장이 촉진될 것으로 예상됩니다. 올라파립과 같은 PARP 억제제가 합성 치사 기반 치료법을 활용하여 DNA 복구 결핍(예: BRCA1 또는 BRCA2 돌연변이) 암 치료에 성공함에 따라, DNA-PK, ATR, ATM, CHK1, WEE1을 포함한 DDR 신호 전달 경로의 표적 가능한 구성 요소를 합성 치사법을 통해 탐색하는 연구가 활발히 진행되고 있습니다. 수년간의 노력 끝에 수많은 DDR 키나제 억제제가 발견되었으며, 그중 일부는 임상 시험 단계에서 암 치료에 대한 유망한 결과를 보여주고 있습니다. 예를 들어, 모이뇨스 데 벤토 병원에서 후원하는 이뮤노프로스트 임상 시험은 현재 진행 중이며, DNA 복구 결함이 있는 전립선암 환자를 대상으로 니볼루맙의 2상 임상 연구를 진행하고 있습니다.
또한, 암 발병률 증가와 시장 개발의 성장은 예측 기간 동안 세계 시장 성장에 기여할 것으로 예상되는 여러 요인 중 하나입니다.

엄격한 규제 당국
그럼에도 불구하고, 개발도상국과 저개발국에서는 규제 당국의 승인에 대한 엄격한 규정, 높은 개발 비용 및 치료 비용이 예측 기간 동안 세계 시장 성장을 저해할 것으로 예상됩니다.
세분화 분석
전 세계 DDR 결함 종양 시장은 분자 유형, 암 유형, 최종 사용자 및 지역별로 세분화됩니다.
생물학적 제제 분자 유형, 시장 주도 예상
DDR 결함 종양에 대한 생물학적 제제를 연구하는 임상 시험 건수가 증가함에 따라, 전 세계 시장에서 생물학적 제제 부문이 예측 기간 동안 시장을 주도할 것으로 예상됩니다. 예를 들어, clinicaltrial.gov에 따르면, M.D. 앤더슨 암센터는 DNA 손상 반응(DDR) 결핍 진행성 고형암 환자를 대상으로 베르조서팁(M6620)과 아벨루맙 병용 요법의 안전성과 내약성을 평가하는 연구를 진행하고 있으며, 예상 완료일은 2024년입니다. 또한, 아산병원은 백금 기반 항암화학요법 후 DDR 유전자 변이 진행성 담도암 환자를 대상으로 올라파립 유지 요법과 두르발루맙 병용 또는 비병용 요법의 효과를 평가하는 무작위 공개 라벨 2상 연구를 진행하고 있으며, 예상 완료일은 2024년입니다.
지역 분석
북미 지역이 세계 시장을 주도할 것으로 예상됨
북미 지역은 주요 시장 참여자들의 연구 개발 증가로 인해 예측 기간 동안 세계 시장을 주도할 것으로 예상됩니다. 예를 들어, 2021년 6월 화이자(Pfizer Inc.)는 다국적, 무작위 배정, 이중 맹검, 위약 대조 3상 임상 시험인 TALAPRO-3의 첫 번째 참가자에게 투약을 시작했습니다.
이 연구는 DNA 손상 반응(DDR) 결핍 전이성 거세 민감성 전립선암(mCSPC) 남성 환자를 대상으로 경구용 폴리(ADP-리보스) 중합효소(PARP) 억제제인 탈라조파립과 안드로겐 수용체 억제제인 엔잘루타미드를 병용 투여했을 때의 효과와 안전성을 위약과 엔잘루타미드를 병용 투여한 경우와 비교 평가하는 것으로 알려져 있습니다.

또한, 2023년 7월, 미국에 본사를 둔 임상 단계 생명공학 기업인 KSQ Therapeutics, Inc.는 로슈와 KSQ-4279의 개발 및 상용화를 위한 전 세계 라이선스 및 협력 계약을 체결했습니다. KSQ-4279는 DNA 손상 반응(DDR)을 조절하는 단백질인 USP1을 강력하고 선택적으로 억제하는 최초의 소분자 저해제로, PARP 저해제를 포함한 다른 기술과는 차별화된 형태를 가지고 있습니다.
COVID-19 영향 분석
COVID-19 팬데믹은 혈액학 및 종양학 임상 시험에 즉각적이고 지연된 결과를 초래하며 상당한 영향을 미쳤습니다. COVID-19 환자 유입에 대처하기 위해 많은 학술 기관과 참여 병원은 연구 인력과 자원을 재배치해야 했고, 이로 인해 일상적인 임상 연구 활동이 중단되었습니다.
또한, COVID-19 치료법을 시험하는 임상 시험이 다른 임상 시험보다 우선시되었습니다. 여행 제한으로 인해 CRO 및 스폰서의 현장 선정 또는 자격 심사, 원천 데이터 검증, 약물 관리, 감사 및 현장 직원 교육을 포함한 연구 관련 일정이 취소되기도 했습니다. 그 결과, 진행 중인 임상시험의 참가자 모집이 급격히 감소했으며, 팬데믹이 절정에 달했을 때 새로운 혈액학 및 종양학 연구의 시작이 지연될 수 있습니다.
시장 세분화
분자 유형별
• 생물학적 제제
• 저분자
암 유형별
• 난소암
• 전립선암
• 유방암
• 췌장암
• 기타
최종 사용자별
• 병원
• 암 연구 센터
• 전문 클리닉
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
주요 개발
• 2023년 1월, DNA 손상 반응(DDR) 경로를 표적으로 하는 새로운 합성 치사 기반 항암 치료제 개발에 주력하는 바이오제약 회사인 Aprea Therapeutics, Inc.는 ATRN-119의 1/2a상 단독 요법 임상 시험에서 첫 번째 환자에게 투약을 시작했습니다. 이 회사의 주요 ATR 억제제는 DDR 돌연변이가 있는 암 치료에 사용됩니다.

• 2021년 7월, 광범위한 DDR 기반 플랫폼과 소분자 신약 개발 역량을 활용하여 암 치료를 위한 다양한 개발 후보 물질 파이프라인을 구축한 DNA 손상 반응(DDR) 분야 선도 기업인 Artios Pharma Limited(Artios)는 유망한 임상 단계 파이프라인의 추가 개발 자금으로 1억 5,300만 달러(1억 1,000만 파운드) 규모의 시리즈 C 투자를 유치했습니다.
경쟁 환경
시장의 주요 글로벌 기업으로는 Artios Pharma Limited, AstraZeneca, Aprea Therapeutics, Inc., KSQ Therapeutics, Inc., Pfizer, Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Daiichi Sankyo Company Limited., Chordia Therapeutics Inc. 및 Repare Therapeutics가 있습니다.
보고서 구매 이유

• 분자 유형, 암 유형, 최종 사용자 및 지역별 DDR 결함 종양 시장의 세분화를 시각화하고 주요 상업 자산 및 주요 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴합니다.

• 모든 세그먼트를 포함한 DDR 결함 종양 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 Excel 파일을 제공합니다.

글로벌 DDR 결함 종양 시장 보고서는 약 61개의 표, 58개의 그림, 184페이지 분량입니다.
대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 연구 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global DDR Defective Tumors market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period 2023-2030.
DDR defect is an innate characteristic of tumor cells that participates not just in cancer initiation, but in cancer advancement and metastasis from considerable aspects. Advanced DDR gene alterations and genomic instability are hallmarks of metastatic growth. DDR (DNA damage response) deficiencies in cells drive tumor building by boosting DNA mutations, which even deliver cancer-specific susceptibilities that can be targeted by synthetic lethality-based therapies.
Market Dynamics: Drivers & Restraints
Increase in Clinical Research Advancements
It is expected that the global market growth will be boosted owing to the increase in clinical research advancements in DDR defective tumors during the forecast period. The success of PARP inhibitors like olaparib in treating cancers with DNA-repairing deficiency (e.g. BRCA1 or BRCA2 mutation) by utilizing synthetic lethality-based therapy has fueled the search for more targetable components in the DDR signaling pathway through synthetic lethality, including DNA-PK, ATR, ATM, CHK1, and WEE1. Numerous DDR kinase inhibitors have been discovered after years of effort, and some of them are undergoing clinical trials, showing promising results for cancer therapy. For instance, the ImmunoProst Trial, sponsored by Hospital Moinhos de Vento, is currently active and investigating Nivolumab in Prostate Cancer With DNA Repair Defects in Phase 2 clinical investigation.
Additionally, the rise in cancer cases and growing market developments are among other factors that are expected to contribute to the global market growth during the forecast period.
Stringent Regulatory Authorities
Nevertheless, stringent regulations for approval from regulatory authorities, high development costs and high treatment costs are in developing and underdeveloped countries are estimated to hamper the global market growth during the forecast period.
Segment Analysis
The global DDR defective tumors market is segmented based on molecule type, cancer type, end user and region.
Biologics Molecule Type is Expected to Dominate Market
The biologics segment of the global market is estimated to dominate the global market during the forecast period due to the increasing number of clinical trials investigating biologics for DDR defect tumors. For instance, according to clinicaltrial.gov, M.D. Anderson Cancer Center is sponsoring a study recruiting patients with DNA damage response (DDR) deficient advanced solid tumors to determine the safety and tolerability of the combination of berzosertib (M6620) and avelumab, with an estimated completion date of 2024. Additionally, Asan Medical Center is sponsoring another study recruiting for a randomized open-labeled phase 2 study of maintenance Olaparib with or without Durvalumab for DDR gene mutated advanced biliary tract cancer following platinum-based chemotherapy, with an estimated completion date of 2024.
Geographical Analysis
North America is Expected to Dominate the Global Market
North America is estimated to dominate the global market during the forecast period owing to the increasing research advancements by key market players in the region. For instance, in June 2021, Pfizer Inc. dosed the first participant in TALAPRO-3, a multinational, randomized, double-blind, placebo-controlled Phase 3 clinical trial.
The study is estimated to assess the effectiveness and safety of talazoparib, an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with enzalutamide, an androgen receptor inhibitor, compared with placebo plus enzalutamide in males with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer (mCSPC).
Moreover, in July 2023, KSQ Therapeutics, Inc., a US-based clinical-stage biotechnology corporation, entered a worldwide license and cooperation contract with Roche for the development and commercialization of KSQ-4279, a first-in-class, powerful, and selective small molecule inhibitor of USP1, a protein that controls DNA damage response (DDR) in a form distinctive from other techniques, including PARP inhibitors.
COVID-19 Impact Analysis
The impact of the COVID-19 pandemic on hematology and oncology clinical trials has been significant, with immediate and delayed consequences. To manage the influx of COVID-19 patients, many academic institutions and participating hospitals have had to reassign research staff and resources, leading to the suspension of routine clinical research activities.
Furthermore, trials testing treatments for COVID-19 have been given priority over other trials. Travel restrictions have also resulted in the cancellation of research-related appointments, including site selection or qualification, source data verification, drug accountability, audit, and site staff training by CROs and sponsors. As a result, there has been a sharp decline in recruitment for ongoing trials, and the launch of new hematology and oncology studies might be delayed during the peak of the pandemic.
Market Segmentation
By Molecule Type
• Biologics
• Small Molecules
By Cancer Type
• Ovarian
• Prostate
• Breast
• Pancreatic
• Others
By End User
• Hospitals
• Cancer Research Centers
• Specialty Clinics
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In January 2023 Aprea Therapeutics, Inc., a biopharmaceutical corporation concentrated on designing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, dosed the first patient in its Phase 1/2a monotherapy clinical trial of ATRN-119, the Company’s principal ATR inhibitor for the therapy of cancers with DDR mutations.
• In July 2021, Artios Pharma Limited (Artios), a top DNA Damage Response (DDR) corporation using a wide DDR-based platform and small molecule drug discovery abilities to design a mixed pipeline of development nominees for the therapy of cancer, secured a US$153 million (£110 million) Series C financing to fund further development of its promising clinical-stage pipeline.
Competitive Landscape
The major global players in the market include Artios Pharma Limited, AstraZeneca, Aprea Therapeutics, Inc., KSQ Therapeutics, Inc., Pfizer, Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Daiichi Sankyo Company Limited., Chordia Therapeutics Inc. and Repare Therapeutics.
Why Purchase the Report?
• To visualize the global DDR defective tumors market segmentation based on molecule type, cancer type, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of DDR defective tumors market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global DDR defective tumors market report would provide approximately 61 tables, 58 figures and 184 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Molecule Type
3.2. Snippet by Cancer Type
3.3. Snippet by End User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increase in Clinical Research Advancements
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Stringent Regulatory Authorities
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Pricing Analysis
5.3. Regulatory Analysis
5.4. Patent Analysis
5.5. Pipeline Analysis
5.6. Unmet Need
5.7. SWOT Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Molecule Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
7.1.2. Market Attractiveness Index, By Molecule Type
7.2. Biologics*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Small Molecules
8. By Cancer Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.1.2. Market Attractiveness Index, By Cancer Type
8.2. Ovarian*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Prostate
8.4. Breast
8.5. Pancreatic
8.6. Others
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Cancer Research Centers
9.4. Specialty Clinics
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Artios Pharma Limited, Inc.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. AstraZeneca
12.3. Aprea Therapeutics, Inc., Inc.
12.4. KSQ Therapeutics, Inc.
12.5. Pfizer, Inc.
12.6. F. Hoffmann-La Roche Ltd,
12.7. Novartis AG
12.8. DAIICHI SANKYO COMPANY, LIMITED.
12.9. Chordia Therapeutics Inc.
12.10. REPARE THERAPEUTICS
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Artios Pharma Limited, Inc., 4.	Key Developments, AstraZeneca, Aprea Therapeutics, Inc., Inc., KSQ Therapeutics, Inc., Pfizer, Inc., F. Hoffmann-La Roche Ltd,, Novartis AG, DAIICHI SANKYO COMPANY, LIMITED., Chordia Therapeutics Inc., REPARE THERAPEUTICS

표 목록 (Tables)

List of Tables

Table 1 Global DDR Defective Tumors Market Value, By Molecule Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global DDR Defective Tumors Market Value, By Cancer Type, 2022, 2026 & 2030 (US$ Million)

Table 3 Global DDR Defective Tumors Market Value, By End User, 2022, 2026 & 2030 (US$ Million)

Table 4 Global DDR Defective Tumors Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 5 Global DDR Defective Tumors Market Value, By Molecule Type, 2022, 2026 & 2030 (US$ Million)

Table 6 Global DDR Defective Tumors Market Value, By Molecule Type, 2021-2030 (US$ Million)

Table 7 Global DDR Defective Tumors Market Value, By Cancer Type, 2022, 2026 & 2030 (US$ Million)

Table 8 Global DDR Defective Tumors Market Value, By Cancer Type, 2021-2030 (US$ Million)

Table 9 Global DDR Defective Tumors Market Value, By End User, 2022, 2026 & 2030 (US$ Million)

Table 10 Global DDR Defective Tumors Market Value, By End User, 2021-2030 (US$ Million)

Table 11 Global DDR Defective Tumors Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 12 Global DDR Defective Tumors Market Value, By Region, 2021-2030 (US$ Million)

Table 13 North America DDR Defective Tumors Market Value, By Molecule Type, 2021-2030 (US$ Million)

Table 14 North America DDR Defective Tumors Market Value, By Cancer Type, 2021-2030 (US$ Million)

Table 15 North America DDR Defective Tumors Market Value, By End User, 2021-2030 (US$ Million)

Table 16 North America DDR Defective Tumors Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America DDR Defective Tumors Market Value, By Molecule Type, 2021-2030 (US$ Million)

Table 18 South America DDR Defective Tumors Market Value, By Cancer Type, 2021-2030 (US$ Million)

Table 19 South America DDR Defective Tumors Market Value, By End User, 2021-2030 (US$ Million)

Table 20 South America DDR Defective Tumors Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe DDR Defective Tumors Market Value, By Molecule Type, 2021-2030 (US$ Million)

Table 22 Europe DDR Defective Tumors Market Value, By Cancer Type, 2021-2030 (US$ Million)

Table 23 Europe DDR Defective Tumors Market Value, By End User, 2021-2030 (US$ Million)

Table 24 Europe DDR Defective Tumors Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific DDR Defective Tumors Market Value, By Molecule Type, 2021-2030 (US$ Million)

Table 26 Asia-Pacific DDR Defective Tumors Market Value, By Cancer Type, 2021-2030 (US$ Million)

Table 27 Asia-Pacific DDR Defective Tumors Market Value, By End User, 2021-2030 (US$ Million)

Table 28 Asia-Pacific DDR Defective Tumors Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East & Africa DDR Defective Tumors Market Value, By Molecule Type, 2021-2030 (US$ Million)

Table 30 Middle East & Africa DDR Defective Tumors Market Value, By Cancer Type, 2021-2030 (US$ Million)

Table 31 Middle East & Africa DDR Defective Tumors Market Value, By End User, 2021-2030 (US$ Million)

Table 32 Artios Pharma Limited, Inc.: Overview

Table 33 Artios Pharma Limited, Inc.: Product Portfolio

Table 34 Artios Pharma Limited, Inc.: Key Developments

Table 35 AstraZeneca: Overview

Table 36 AstraZeneca: Product Portfolio

Table 37 AstraZeneca: Key Developments

Table 38 Aprea Therapeutics, Inc., Inc.: Overview

Table 39 Aprea Therapeutics, Inc., Inc.: Product Portfolio

Table 40 Aprea Therapeutics, Inc., Inc.: Key Developments

Table 41 KSQ Therapeutics, Inc.: Overview

Table 42 KSQ Therapeutics, Inc.: Product Portfolio

Table 43 KSQ Therapeutics, Inc.: Key Developments

Table 44 Pfizer, Inc.: Overview

Table 45 Pfizer, Inc.: Product Portfolio

Table 46 Pfizer, Inc.: Key Developments

Table 47 F. Hoffmann-La Roche Ltd,: Overview

Table 48 F. Hoffmann-La Roche Ltd,: Product Portfolio

Table 49 F. Hoffmann-La Roche Ltd,: Key Developments

Table 50 Novartis AG: Overview

Table 51 Novartis AG: Product Portfolio

Table 52 Novartis AG: Key Developments

Table 53 Daiichi Sankyo Company, Limited.: Overview

Table 54 Daiichi Sankyo Company, Limited.: Product Portfolio

Table 55 Daiichi Sankyo Company, Limited.: Key Developments

Table 56 Chordia Therapeutics Inc.: Overview

Table 57 Chordia Therapeutics Inc.: Product Portfolio

Table 58 Chordia Therapeutics Inc.: Key Developments

Table 59 REPARE THERAPEUTICS: Overview

Table 60 REPARE THERAPEUTICS: Product Portfolio

Table 61 REPARE THERAPEUTICS: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global DDR Defective Tumors Market Value, 2021-2030 (US$ Million)

Figure 2 Global DDR Defective Tumors Market Share, By Molecule Type, 2022 & 2030 (%)

Figure 3 Global DDR Defective Tumors Market Share, By Cancer Type, 2022 & 2030 (%)

Figure 4 Global DDR Defective Tumors Market Share, By End User, 2022 & 2030 (%)

Figure 5 Global DDR Defective Tumors Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global DDR Defective Tumors Market Y-o-Y Growth, By Molecule Type, 2022-2030 (%)

Figure 7 Biologics DDR Defective Tumors Market Value, 2021-2030 (US$ Million)

Figure 8 Small Molecules DDR Defective Tumors Market Value, 2021-2030 (US$ Million)

Figure 9 Global DDR Defective Tumors Market Y-o-Y Growth, By Cancer Type, 2022-2030 (%)

Figure 10 Ovarian Cancer Type in Global DDR Defective Tumors Market Value, 2021-2030 (US$ Million)

Figure 11 Prostate Cancer Type in Global DDR Defective Tumors Market Value, 2021-2030 (US$ Million)

Figure 12 Breast Cancer Type in Global DDR Defective Tumors Market Value, 2021-2030 (US$ Million)

Figure 13 Pancreatic Cancer Type in Global DDR Defective Tumors Market Value, 2021-2030 (US$ Million)

Figure 14 Others Cancer Type in Global DDR Defective Tumors Market Value, 2021-2030 (US$ Million)

Figure 15 Global DDR Defective Tumors Market Y-o-Y Growth, By End User, 2022-2030 (%)

Figure 16 Hospitals End User in Global DDR Defective Tumors Market Value, 2021-2030 (US$ Million)

Figure 17 Cancer Research Centers End User in Global DDR Defective Tumors Market Value, 2021-2030 (US$ Million)

Figure 18 Specialty Clinics End User in Global DDR Defective Tumors Market Value, 2021-2030 (US$ Million)

Figure 19 Global DDR Defective Tumors Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 20 North America DDR Defective Tumors Market Value, 2021-2030 (US$ Million)

Figure 21 Asia-Pacific DDR Defective Tumors Market Value, 2021-2030 (US$ Million)

Figure 22 Europe DDR Defective Tumors Market Value, 2021-2030 (US$ Million)

Figure 23 South America DDR Defective Tumors Market Value, 2021-2030 (US$ Million)

Figure 24 Middle East and Africa DDR Defective Tumors Market Value, 2021-2030 (US$ Million)

Figure 25 North America DDR Defective Tumors Market Value, 2021-2030 (US$ Million)

Figure 26 North America DDR Defective Tumors Market Share, By Molecule Type, 2022 & 2030 (%)

Figure 27 North America DDR Defective Tumors Market Share, By Cancer Type, 2022 & 2030 (%)

Figure 28 North America DDR Defective Tumors Market Share, By End User, 2022 & 2030 (%)

Figure 29 North America DDR Defective Tumors Market Share, By Country, 2022 & 2030 (%)

Figure 30 South America DDR Defective Tumors Market Value, 2021-2030 (US$ Million)

Figure 31 South America DDR Defective Tumors Market Share, By Molecule Type, 2022 & 2030 (%)

Figure 32 South America DDR Defective Tumors Market Share, By Cancer Type, 2022 & 2030 (%)

Figure 33 South America DDR Defective Tumors Market Share, By End User, 2022 & 2030 (%)

Figure 34 South America DDR Defective Tumors Market Share, By Country, 2022 & 2030 (%)

Figure 35 Europe DDR Defective Tumors Market Value, 2021-2030 (US$ Million)

Figure 36 Europe DDR Defective Tumors Market Share, By Molecule Type, 2022 & 2030 (%)

Figure 37 Europe DDR Defective Tumors Market Share, By Cancer Type, 2022 & 2030 (%)

Figure 38 Europe DDR Defective Tumors Market Share, By End User, 2022 & 2030 (%)

Figure 39 Europe DDR Defective Tumors Market Share, By Country, 2022 & 2030 (%)

Figure 40 Asia-Pacific DDR Defective Tumors Market Value, 2021-2030 (US$ Million)

Figure 41 Asia-Pacific DDR Defective Tumors Market Share, By Molecule Type, 2022 & 2030 (%)

Figure 42 Asia-Pacific DDR Defective Tumors Market Share, By Cancer Type, 2022 & 2030 (%)

Figure 43 Asia-Pacific DDR Defective Tumors Market Share, By End User, 2022 & 2030 (%)

Figure 44 Asia-Pacific DDR Defective Tumors Market Share, By Country, 2022 & 2030 (%)

Figure 45 Middle East & Africa DDR Defective Tumors Market Value, 2021-2030 (US$ Million)

Figure 46 Middle East & Africa DDR Defective Tumors Market Share, By Molecule Type, 2022 & 2030 (%)

Figure 47 Middle East & Africa DDR Defective Tumors Market Share, By Cancer Type, 2022 & 2030 (%)

Figure 48 Middle East & Africa DDR Defective Tumors Market Share, By End User, 2022 & 2030 (%)

Figure 49 Artios Pharma Limited, Inc.: Financials

Figure 50 AstraZeneca: Financials

Figure 51 Aprea Therapeutics, Inc., Inc.: Financials

Figure 52 KSQ Therapeutics, Inc.: Financials

Figure 53 Pfizer, Inc.: Financials

Figure 54 F. Hoffmann-La Roche Ltd, Financials

Figure 55 Novartis AG: Financials

Figure 56 DAIICHI SANKYO COMPANY, LIMITED.: Financials

Figure 57 Chordia Therapeutics Inc.: Financials

Figure 58 REPARE THERAPEUTICS: Financials

전 세계 DDR 결함 종양 – 2023-2030

Global DDR Defective Tumors - 2023-2030